Aptose Biosciences (NASDAQ:APTO) Earns “Buy” Rating from HC Wainwright

Aptose Biosciences (NASDAQ:APTO) (TSE:APS)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $2.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com began coverage on Aptose Biosciences in a research note on Wednesday. They issued a “hold” rating for the company.

Aptose Biosciences Price Performance

Shares of APTO stock opened at $0.22 on Friday. The stock has a fifty day moving average price of $0.25 and a 200 day moving average price of $0.40. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.48. The stock has a market cap of $13.24 million, a P/E ratio of -0.07 and a beta of 0.87.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp increased its holdings in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.